You have printed or saved this information from www.HorizonNB.ca, the website for the Horizon Health Network

Facebook Icon LinkedIn Icon Twitter Icon Icon Icon
Print this page

Current Active Trials

ATMOSPHERE - Principal Investigator: Dr. Gregory Searles

Evaluate the effects of aliskiren (a renin blocker) and aliskerin/ enalapril combination therapy on top of conventional CHF therapy.

BRUISE CONTROL - Principal Investigator: Dr. Satish Toal

Evaluate the use of continuation of Coumadin at the time of  Pacemaker or Implantable Defibrillator device implantation surgery, in patients with moderate to high risk of thrombo-embolic events.

CAIN-003 - Principal Investigator: Dr. Robert Teskey

Evaluating plaque burden as measured by intravascular ultrasound (IVUS) and carotid ultrasound in order to assess correlations between vascular beds, imaging technologies and major cardiovascular events.

GENESIS PRAXY - Principal Investigator: Dr. Peter Fong

The purpose of this study is to explore sex differences in key factors (behavioural, environmental, psychosocial, clinical and biological) of the presentation and prognosis of early heart attacks, as well as differences in health services utilization, satisfaction with care and quality of life.

TAO - Principal Investigator: Dr. Sohrab Lutchmedial

The purpose of this study is to evaluate the effectiveness and the possible risks of Otamixaban (a novel anticoagulant) compared to unfractionated heparin (well-known standard blood thinner) and eptifibatide (intravenous antiplatelet medication), on a background of aspirin and clopidogrel (Oral antiplatelet medication).

TRIPLET -Principal Investigator: Dr. Sohrab Lutchmedial

Evaluate the use of Prasugrel 30 or 60mg loading dose administered during PCI, with and without a prior loading dose of clopidogrel on platelet inhibition in patients presenting with ACS

VELETI II -Principal Investigator: Dr. Vernon Paddock

Evaluate the efficacy of stenting moderate SVG lesions with paclitaxel-eluding stents on reducing the first occurrence of the composite of cardiac death, MI, or repeat revascularization related to the target SVG over a minimum 2 year follow up.

VISTA  16 -Principal Investigator: Dr Colin Barry

Evaluating the safety and efficacy of short term A-002 (investigational anti inflammatory) treatment when added to atorvastatin and standard of care in subjects with an acute coronary syndrome.

Facebook Icon LinkedIn Icon Twitter Icon Icon Icon
Text Size:

Helpful Links